Oral immunology pipeline drives Chimera valuation
Chimera Therapeutics' targeted protein degradation platform offers a path to replace injectable biologics with oral pills for common allergic diseases like eczema, opening a massive underserved patient market.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.